FDA panel backs Teva’s new abuse-deterrent opioid
US Food and Drug Administration advisors have backed approval of Teva’s abuse-deterrent opioid Vantrela ER.
Read More
Tag: Vantrela
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
